In this week's edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more.
Read the full coverage here:
Labcorp blood test identifies signs of neurodegenerative disease
FDA approves oral treatment for partial seizures in patients aged 16 years and older
Ketamine effective treatment for neonatal, pediatric epilepsy
FDA places hold on phase 2/3 clinical trial of stroke therapy
Hypertension, obesity, physical inactivity among highest risk factors for dementia
References:
Jacobwitz M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200889.
Lee M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.19672.
